Moleculin

MBRX NASDAQ
1.210
-0.060
-4.72%
After Hours: 1.230 +0.02 +1.65% 16:16 06/24 EDT
Open
1.280
Prev Close
1.270
High
1.280
Low
1.200
Volume
349.69K
Avg Vol (3M)
3.76M
52 Week High
3.150
52 Week Low
0.7772
% Turnover
0.77%
Market Cap
54.68M
1D
5D
1M
3M
1Y
5Y

Company Profile

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
MORE >

Recently

Name
Price
%Change